Statins use may increase risk of cataract and diabetes in kidney transplant recipients

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-07-16 15:00 GMT   |   Update On 2023-07-17 05:55 GMT

Statins use may increase risk of cataract and diabetes in kidney transplant recipients suggests a new study published in the Clinical Journal of the American Society of NephrologyStatins are the third most prescribed drug class in kidney transplant recipients as cardiovascular disease is the leading cause of death in this population. However, statins' safety profile remains unclear in...

Login or Register to read the full article

Statins use may increase risk of cataract and diabetes in kidney transplant recipients suggests a new study published in the Clinical Journal of the American Society of Nephrology

Statins are the third most prescribed drug class in kidney transplant recipients as cardiovascular disease is the leading cause of death in this population. However, statins' safety profile remains unclear in kidney transplant recipients who are uniquely burdened by concomitant immunosuppression and comorbidities. They conducted a national study to characterize the association of statin use with adverse events in kidney transplant recipients.

They studied adult (18 years or older) single-organ kidney transplant recipients in 2006–2016 with Medicare as primary payer (n=57,699). We used prescription drug claims to capture statin use and International Classification of Diseases 9/10 diagnosis codes to capture statin-related adverse events (post-transplant diabetes mellitus, hemorrhagic stroke, cataract, liver injury, and rhabdomyolysis). We conducted multivariable Cox regression for each outcome with statin use as a time-varying exposure.

Results

Post-transplant diabetes mellitus was the most common outcome (5-year Kaplan–Meier incidence; 43% in statin users versus 35% in nonusers), followed by cataract (22% versus 12%), liver injury (2% versus 3%), hemorrhagic stroke (1.9% versus 1.4%), and rhabdomyolysis (1.5% versus 0.9%). In our multivariable analysis, statin use was associated with higher hazard of post-transplant diabetes mellitus (adjust hazard ratio [aHR], 1.12; 95% confidence interval [95% CI], 1.07 to 1.18), cataract (aHR, 1.22; 95% CI, 1.14 to 1.31), and rhabdomyolysis (aHR, 1.37; 95% CI, 1.10 to 1.71) but lower hazard of liver injury (aHR, 0.82; 95% CI, 0.71 to 0.95). Statin use was not associated with hemorrhagic stroke (aHR, 1.04; 95% CI, 0.86 to 1.26).


Statins seem to be generally well tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.

Reference:

Bae, Sunjae; Ahn, JiYoon B.; Joseph, Corey; Whisler, Ryan; Schnitzler, Mark A.; Lentine, Krista L.; Kadosh, Bernard S.; Segev, Dorry L.; McAdams-DeMarco, Mara A.. Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology 18(5):p 626-633, May 2023. | DOI: 10.2215/CJN.0000000000000124

Keywords:

Statins, use, may, increase, risk, cataract, diabetes, kidney, transplant, recipients, Incidence, Statin-Associated, Adverse, Events, Kidney, Transplant, Recipients, Bae, Sunjae; Ahn, JiYoon B.; Joseph, Corey; Whisler, Ryan; Schnitzler, Mark A.; Lentine, Krista L.; Kadosh, Bernard S.; Segev, Dorry L.; McAdams-DeMarco, Mara A, Clinical Journal of the American Society of Nephrology





Tags:    
Article Source : Clinical Journal of the American Society of Nephrology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News